Glucagon-Like Peptide 1

"Glucagon-Like Peptide 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A peptide of 36 or 37 amino acids that is derived from PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. GLP-1(1-37 or 1-36) is further N-terminally truncated resulting in GLP-1(7-37) or GLP-1-(7-36) which can be amidated. These GLP-1 peptides are known to enhance glucose-dependent INSULIN release, suppress GLUCAGON release and gastric emptying, lower BLOOD GLUCOSE, and reduce food intake.

Descriptor ID	D052216
MeSH Number(s)	D06.472.317.469.500.500
Concept/Terms	Glucagon-Like Peptide 1 Glucagon-Like Peptide 1 Glucagon Like Peptide 1 Glucagon-Like Peptide-1 GLP-1 GLP 1

Below are MeSH descriptors whose meaning is more general than "Glucagon-Like Peptide 1".

Chemicals and Drugs [D]
Hormones, Hormone Substitutes, and Hormone Antagonists [D06]
Hormones [D06.472]
Gastrointestinal Hormones [D06.472.317]
Proglucagon [D06.472.317.469]
Glucagon-Like Peptides [D06.472.317.469.500]
Glucagon-Like Peptide 1 [D06.472.317.469.500.500]

Below are MeSH descriptors whose meaning is related to "Glucagon-Like Peptide 1".

Below are MeSH descriptors whose meaning is more specific than "Glucagon-Like Peptide 1".

Glucagon-Like Peptide 1
Liraglutide

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Glucagon-Like Peptide 1" by people in this website by year, and whether "Glucagon-Like Peptide 1" was a major or minor topic of these publications.

Bar chart showing 25 publications over 17 distinct years, with a maximum of 3 publications in 2013 and 2024

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2001	0	1	1
2005	1	0	1
2006	1	1	2
2007	1	0	1
2008	1	0	1
2009	1	0	1
2011	1	1	2
2013	2	1	3
2015	0	1	1
2016	2	0	2
2017	1	0	1
2018	1	0	1
2020	1	0	1
2022	1	0	1
2023	0	2	2
2024	0	3	3
2025	0	1	1

Below are the most recent publications written about "Glucagon-Like Peptide 1" by people in Profiles.

Havranek B, Loh R, Torre B, Redfield R, Halegoua-DeMarzio D. Glucagon-like peptide-1 receptor agonists improve metabolic dysfunction-associated steatotic liver disease outcomes. Sci Rep. 2025 02 10; 15(1):4947.

View in: PubMed
Harrison DB, Phillips AL, Tansey JB, Clarke TJ, Wood CB, Nedzi L, Schwartz DL, Makowski L, Hayes DN, Newman G, Gleysteen JP. Brown Adipose Tissue Mimicking Head and Neck Cancer on PET Scan in a Patient on GLP-1 Drug. Laryngoscope. 2025 02; 135(2):741-743.

View in: PubMed
Qaseem A, Obley AJ, Shamliyan T, Hicks LA, Harrod CS, Crandall CJ, Balk EM, Cooney TG, Cross JT, Fitterman N, Lin JS, Maroto M, Miller MC, Shekelle P, Tice JA, Tufte JE, Etxeandia-Ikobaltzeta I, Yost J. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians. Ann Intern Med. 2024 05; 177(5):658-666.

View in: PubMed
Parkman HP, Rim DS, Anolik JR, Dadparvar S, Maurer AH. Glucagonlike Peptide-1 Receptor Agonists: The Good, the Bad, and the Ugly-Benefits for Glucose Control and Weight Loss with Side Effects of Delaying Gastric Emptying. J Nucl Med Technol. 2024 Mar 05; 52(1):3-7.

View in: PubMed
Lin TY, Kang EY, Shao SC, Lai EC, Garg SJ, Chen KJ, Kang JH, Wu WC, Lai CC, Hwang YS. Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. Diabetes Metab J. 2023 05; 47(3):394-404.

View in: PubMed
Wai KM, Saroj N, Boucher N, Aggarwal N, Ho AC, Rahimy E. Evaluating the Effect of Hypoglycemic Agents on Diabetic Retinopathy Progression. Ophthalmic Surg Lasers Imaging Retina. 2023 03; 54(3):158-165.

View in: PubMed
Danowitz M, De Leon DD. The Role of GLP-1 Signaling in Hypoglycemia due to Hyperinsulinism. Front Endocrinol (Lausanne). 2022; 13:863184.

View in: PubMed
Vernet E, Pedersen M?, Th?gersen H, Shaw AC. Engineering Xaa-Pro dipeptidyl aminopeptidase for specific cleavage of glucagon and glucagon-like peptide 1 from fusion proteins. Protein Expr Purif. 2020 06; 170:105590.

View in: PubMed
Moellmann J, Klinkhammer BM, Onstein J, St?hr R, Jankowski V, Jankowski J, Lebherz C, Tacke F, Marx N, Boor P, Lehrke M. Glucagon-Like Peptide 1 and Its Cleavage Products Are Renoprotective in Murine Diabetic Nephropathy. Diabetes. 2018 11; 67(11):2410-2419.

View in: PubMed
Bouhlal S, Ellefsen KN, Sheskier MB, Singley E, Pirard S, Gorelick DA, Huestis MA, Leggio L. Acute effects of intravenous cocaine administration on serum concentrations of ghrelin, amylin, glucagon-like peptide-1, insulin, leptin and peptide YY and relationships with cardiorespiratory and subjective responses. Drug Alcohol Depend. 2017 11 01; 180:68-75.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement